NI200900057A - Terapia de combinación en secuencia - Google Patents

Terapia de combinación en secuencia

Info

Publication number
NI200900057A
NI200900057A NI200900057A NI200900057A NI200900057A NI 200900057 A NI200900057 A NI 200900057A NI 200900057 A NI200900057 A NI 200900057A NI 200900057 A NI200900057 A NI 200900057A NI 200900057 A NI200900057 A NI 200900057A
Authority
NI
Nicaragua
Prior art keywords
combination therapy
sequence combination
disorders related
antigenis
angiogenesis
Prior art date
Application number
NI200900057A
Other languages
English (en)
Inventor
K Jain Rakesh
R Wood Clive
T Dransfield Daniel
Arulanandam Antonio
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of NI200900057A publication Critical patent/NI200900057A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se divulgan nuevos métodos de tratamiento de trastornos relacionados con la angiogénesis. Los trastornos relacionados con la antigénesis se tratan por la administración de una agente de uniónal ectodominio Tie1 y de un agente antagonista de VEGF.-
NI200900057A 2006-10-17 2009-04-16 Terapia de combinación en secuencia NI200900057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85226306P 2006-10-17 2006-10-17
US87573606P 2006-12-19 2006-12-19

Publications (1)

Publication Number Publication Date
NI200900057A true NI200900057A (es) 2010-02-02

Family

ID=39314809

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200900057A NI200900057A (es) 2006-10-17 2009-04-16 Terapia de combinación en secuencia

Country Status (17)

Country Link
US (1) US20080160019A1 (es)
EP (1) EP2073826A4 (es)
JP (1) JP2010506951A (es)
KR (1) KR20090067214A (es)
AU (1) AU2007311092A1 (es)
BR (1) BRPI0717760A2 (es)
CA (1) CA2666714A1 (es)
CR (1) CR10798A (es)
EA (1) EA200900562A1 (es)
EC (1) ECSP099336A (es)
IL (1) IL198026A0 (es)
MA (1) MA30901B1 (es)
MX (1) MX2009004070A (es)
NI (1) NI200900057A (es)
NO (1) NO20091375L (es)
TN (1) TN2009000136A1 (es)
WO (1) WO2008048996A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2535171A1 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
US20080260861A1 (en) * 2004-04-07 2008-10-23 The General Hospital Corporation Modulating Lymphatic Function
US20080213253A1 (en) * 2007-01-12 2008-09-04 Dyax Corp. Combination therapy for the treatment of cancer
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
WO2011121560A2 (en) * 2010-03-31 2011-10-06 Universite De Geneve Stabilized antibody preparations and uses thereof
US20150003204A1 (en) * 2013-06-27 2015-01-01 Elwha Llc Tactile feedback in a two or three dimensional airspace
US9804675B2 (en) 2013-06-27 2017-10-31 Elwha Llc Tactile feedback generated by non-linear interaction of surface acoustic waves

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514918A (en) * 1999-04-28 2003-11-28 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting VEGF
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
CA2535171A1 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
AU2005272848A1 (en) * 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
US20080213253A1 (en) * 2007-01-12 2008-09-04 Dyax Corp. Combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
MA30901B1 (fr) 2009-11-02
WO2008048996A3 (en) 2008-07-03
US20080160019A1 (en) 2008-07-03
EP2073826A4 (en) 2010-12-15
ECSP099336A (es) 2009-06-30
BRPI0717760A2 (pt) 2013-11-12
KR20090067214A (ko) 2009-06-24
CA2666714A1 (en) 2008-04-24
JP2010506951A (ja) 2010-03-04
MX2009004070A (es) 2009-04-27
TN2009000136A1 (en) 2010-10-18
IL198026A0 (en) 2011-08-01
CR10798A (es) 2009-06-09
WO2008048996A2 (en) 2008-04-24
WO2008048996A9 (en) 2008-09-12
EP2073826A2 (en) 2009-07-01
EA200900562A1 (ru) 2009-10-30
NO20091375L (no) 2009-07-10
AU2007311092A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
NI200900057A (es) Terapia de combinación en secuencia
MX2019011679A (es) Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular.
RS52102B (en) PIRPHENIDONE THERAPY Avoiding FLUVOXAMINE
EA200800835A1 (ru) Циклопропиламины в качестве модуляторов рецептора гистамина н
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2009009428A (es) Analogos de ciclopamina heterociclicos y metodos de uso de los mismos.
CY2014006I2 (el) Μεθοδοι θεραπευτικης αγωγης χρησιμοποιωντας γλυκοπεγκυλιωμενο g-csf
MA32161B1 (fr) Formes de rifaximine et utilisations de celles-ci
MX2009008132A (es) Terapia de combinacion con inhibidores de angiogenesis.
HK1139930A1 (en) Cyclopamine lactam analogs and methods of use thereof
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
NO20054371L (no) Somatostatin-dopamin kimaere analoger
DK2114531T3 (da) Punktpropper og fremgangsmåder til indgivelse af terapeutiske midler
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
PA8651301A1 (es) Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
BR112012021296A2 (pt) imunoconjugados e anticorpos de receptor de folato 1 e usos dos mesmos.
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
EA201070637A1 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н